Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Aspire Mining pleased with 'very good commercial outcomes' from rail feasibility study

2018-06-21 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) managing director David Paull speaks to Proactive Investors about the review of a rail feasibility study, carried out by wholly-owned rail subsidiary Northern Railways LLC, with the support of China Gezhouba International Ltd. This 547.7 kilometer railway extension will connect Aspire Mining’s large-scale Ovoot Coking Coal Project to the the town of Erdenet, and form part of the proposed Northern Rail Corridor extending across northern Mongolia into southern Russia.
ASPXF AKM

0
Aspire Mining coking coal test results confirm premium product

2018-06-17 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) has received results from pilot-scale carbonisation test work on a 300-kilogram bulk sample from its Nuurstei Coking Coal Project in Mongolia.
ASPXF AKM

0
Aspire Mining welcomes new Russia-Mongolia agreement lowering rail transit costs

2018-06-13 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) stands to gain from the new cooperation agreement signed between Russia and Mongolia.
ASPXF AKM

0
Aspire Mining responds to ASX price and volume query

2018-06-12 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) yesterday received a query from the ASX related to the company’s shares rising from 2.1 cents last Friday to 2.7 cents yesterday.
ASPXF AKM

0
Aspire Mining feasibility study review reduces railway construction cost

2018-06-04 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) has completed its review of the 547.7-kilometre Erdenet to Ovoot rail feasibility study.
ASPXF AKM

0
Aspire Mining major shareholder purchases more stock on market

2018-05-30 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) has had major shareholder, Tserenpuntsag Tserendamba, increase its stake in the company to 16.10% from 14.77%.
ASPXF AKM

0
Aspire Mining welcomes growing support for rail for its coal mine

2018-05-21 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) stands to gain from the growing support for the Erdenet to Ovoot Railway from both within Mongolia and the Tuva Republic in the Russian Federation.
ASPXF AKM

0
Aspire Mining is one of the most traded stocks on the ASX today

2018-05-11 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) is one of the most traded stocks today on the ASX by share volume.
ASPXF AKM

0
Aspire Mining receives speeding ticket from ASX after shares surge 25% under high volumes

2018-04-24 proactiveinvestors.com.au
In the absence of any news relating to those projects, the ASX has queried the share price spike.
ASXFF ASXFY ASPXF AKM

0
Aspire Mining on track with railway to exploit major Mongolian coking coal project

2018-04-20 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) managing director David Paull says "as a relatively small cap company, we've got our foot on a real giant, and realising the value in that giant is really what we're aiming to do through this year." The company’s plans for 2018 are focused on developing coking coal deposits in Mongolia to deliver international specification product to neighbouring international consumers.
ASPXF AKM

0
Aspire Mining has numerous share price catalysts on the horizon

2018-04-17 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) has two key assets in Mongolia, the wholly-owned Ovoot Coking Coal Project and a 90% stake in the Nuurstei Coking Coal Project.
ASPXF AKM

0
Aspire Mining enters new MoU to progress railway for coal project

2018-04-12 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) has entered into a new memorandum of understanding (MoU) with China Gezhouba Group International Engineering Co Ltd (CGGC).
ASPXF AKM

0
Aspire Mining appoints experienced corporate executive to its board

2018-04-10 proactiveinvestors.com.au
This fills a vacancy on the board of the Mongolian focused coal company caused by the recent retirement of long-serving non-executive chair David McSweeney.
ASPXF AKM

0
Aspire Mining sends bulk Nuurstei coal sample for coke oven testing

2018-03-21 proactiveinvestors.com.au
Aspire Mining Ltd (ASX:AKM) is advancing a feasibility study for the Nuurstei Coking Coal Project in northern Mongolia with a bulk sample sent for coke oven testing.
ASPXF AKM

0
Aspire Mining receives draft study that confirms financial viability of Mongolian rail route

2018-03-21 proactiveinvestors.com.au
Aspire Mining Ltd’s (ASX:AKM) rail subsidiary Northern Railways LLC has received a draft feasibility study which confirms the financial viability of the Erdenet to Ovoot Railway in Mongolia.
ASPXF AKM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

42m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...